Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
Trader Note — 15397 total
Armata Pharmaceuticals filed Q1 results after the close on May 13, and the headline EPS of -$3.16 missed the -$0.38 consensus by a wide margin. Revenue of $789K came in ahead of the prior year's $491K, but the earnings…
Dow Inc. heads into the back half of May with shorts rebuilding sharply and options traders tilting more defensive, even as a fresh analyst upgrade and a clutch of post-earnings target raises pull the Street in the…
Equillium just delivered its Q1 2026 results — and the headline is a miss. The company reported EPS of $(0.06) against a consensus estimate of $(0.04) to $(0.05), a shortfall that lands on the same evening the stock…
ALLO just delivered its Q1 2026 results, and the headline number came in better than feared. EPS landed at -$0.18, a penny ahead of the -$0.19 consensus. The stock is up about 6% on the week at $2.30. Yet short sellers…
USA Compression Partners heads into the back half of May with its best weekly performance in months, while the Street edges cautiously higher on the name — a combination that sets up a quiet but interesting tension…
SPIR enters the post-earnings session with a sharper story than most weeks: Q1 results landed after the close on May 13 and beat on every major line, yet short sellers — who have been building positions aggressively…
International Money Express heads into the post-earnings stretch with short sellers backing away fast — even as the company just missed estimates by a wide margin. The headline tension is a striking divergence: IMXI…
Aquestive Therapeutics heads into its Q1 earnings release tomorrow with the entire C-suite having sold shares within the past week — a cluster of insider exits that frames everything else on the tape. The insider…
Wrap Technologies filed Q1 results after the close on May 13, and the headline numbers landed ahead of depressed expectations — yet the stock has barely moved, down 2% on the week to $1.43, with shorts starting to…
OET reports Q1 2026 results after the Oslo close today, with the earnings call scheduled for tomorrow morning. The stock has climbed 12% over the past month to NOK 524, and the setup heading into the print is one of…
AVGO heads into its June 3 earnings with a clean short-interest picture, a fresh analyst target raise from Citigroup, and insider selling from the spring that now looks like routine plan activity rather than a warning…
Lunai Bioworks heads into tomorrow's Q3 earnings print with a genuinely charged setup: short interest has more than doubled in a week, borrowing costs remain historically extreme, and the company itself has gone to war…
RETO enters its May 19 earnings date with a dramatic short position collapse as its 4-to-1 reverse stock split — effective May 18 — dominates the narrative. The headline this week is the speed of the short unwind.…
NEXA enters the post-earnings period with a sharp weekly loss and a puzzling mismatch: short interest is building fast while the borrow market points to anything but a crowded short. The week's defining moment came…
Spero Therapeutics just reported Q1 2026 results after the close on May 13, and the headline numbers tell a split story: EPS of -$0.13 beat the -$0.18 estimate, but quarterly revenue collapsed to $258K from $5.9M a…
APi Group heads into its Q1 2026 earnings call on May 15 with two of its most senior figures having sold tens of millions in stock this week — a strikingly visible signal ahead of the company's biggest near-term…
TI heads into the mid-May session with two catalysts landing on the same morning — a Q1 earnings release showing 22% revenue growth and a cooperation agreement with Teck Resources to evaluate germanium recovery from…
Genprex, Inc. enters its Q1 2026 earnings print — released today after market — with short sellers having aggressively rebuilt positions over the past month, the stock already 28% lower, and a deeply oversold tape that…
MRMD just reported Q1 2026 results after the close on May 13, beating the revenue consensus estimate of $38.75M with $39.48M in sales. The earnings call follows on May 14. That puts the stock at an interesting juncture…
Eledon Pharmaceuticals approaches its May 19 Q1 earnings report with a notable shift in positioning: short sellers have been covering, the stock is up 26% in a month, and the borrow market remains undemanding — a setup…
